I’ve sat in on a few conversations with HR and exec teams where a complex neurological case quietly derails everything — absence spikes, managers feel out of their depth, and claims start dragging on. By the time it reaches leadership, it’s already expensive, disruptive, and avoidable.
The reality is this: one in six people in the UK lives with a neurological condition and that’s 16.5 million cases across England alone. In any mid-to-large organisation, this isn’t an edge case; it’s embedded in your workforce. Conditions like multiple sclerosis, Parkinson’s disease, and motor neurone disease don’t fit neatly into standard occupational health models. They require sustained, coordinated intervention. And what I see repeatedly is organisations trying to manage this complexity with tools that were never designed for it.
At the same time, the business pressure is intensifying. Employees are now averaging 9.4 days of sickness absence annually, up from 5.8 pre-pandemic. Mental ill health, often sitting alongside neurological conditions, accounts for 41% of long-term absence. This is no longer just a wellbeing conversation; it’s a financial one. Add in rising presenteeism, increasing turnover costs, and extended NHS neurology waiting lists, and the system starts to strain from every angle. The Health and Safety Executive reported 1.9 million work-related ill health cases in 2024 alone, spanning stress, musculoskeletal issues, and neurological decline. Against that backdrop, the organisations that are coping better are the ones leaning on specialist brokers — not as intermediaries, but as operators.
The Fragmented Reality of Neurological Care
If you’ve ever tried to map a neurological care pathway end-to-end, you’ll know how quickly it breaks down. Epilepsy, Huntington’s, and other progressive conditions demand input across neurology, physiotherapy, mental health, and social care. Yet access to rehabilitation remains frustratingly inconsistent. NICE has already highlighted the need for dedicated complex case managers across England’s 42 integrated care boards to bring some coherence to this fragmentation.
The scale of the issue is significant. Over 10 million people are living with neurological conditions that materially affect their lives, with at least 1 million experiencing disability as a result. Emergency admissions linked to these conditions have risen by 21% in recent years. Inside organisations, that translates directly into disrupted productivity and an increasing reliance on both NHS and private pathways, neither of which are easy to navigate.
This is where specialist brokers start to matter. The good ones aren’t just placing insurance; they understand the gaps. They know where standard private medical insurance falls short, whether that’s capped physiotherapy sessions or limited access to neuro-rehabilitation at home. Because of their relationships with providers like BUPA, AXA Health, and Vitality, they can reshape policies to reflect the realities of chronic neurological care.
They are a few brokers that benchmark schemes against Mercer and Deloitte frameworks to ensure neurodiversity is properly accounted for. That’s not just progressive; it’s necessary for compliance with the Equality Act.
Brokers as Navigators, Not Middlemen
The difference becomes most obvious when a complex case hits the system.
Take traumatic brain injury which affects around 1.3 million people in the UK. Without coordination, employees end up stuck between NHS pathways and private providers, with delays at every step. What effective brokers do is step in and actively manage that journey: pushing claims through, securing specialist referrals, and aligning care across providers.
They’re also one of the few players in the system operating with FCA-regulated independence, which matters when structuring benefits like income protection. For progressive neurological conditions, that can include escalators that adjust as the condition deteriorates, reducing long-term financial exposure for employers tied to statutory sick pay obligations comes in very useful.
What’s often overlooked is their role upstream. The stronger brokers are using HSE data and internal claims trends to model absence risk before it escalates. They’re advising on interventions like digital symptom tracking and integrated wellbeing programmes which becomes particularly important when you consider the 964,000 cases of work-related stress, depression, or anxiety reported in 2024, many of which overlap with neurological conditions.
And critically, they’re acting as a single point of coordination — something NICE has already identified as essential. That alone removes a huge administrative burden from HR teams who are otherwise left trying to orchestrate this internally.
The ROI Question — And Why It’s No Longer Optional
There’s a tendency to see broker involvement as an added cost. In reality, it’s increasingly a cost control mechanism.
CIPD data shows that long-term absence is now dominated by chronic conditions, with musculoskeletal issues, often linked to neurological decline, accounting for 31% of cases. Left unmanaged, these cases are expensive. When handled properly, outcomes shift quickly.
I’ve heard of cases where early access to neuro-rehabilitation significantly shortens recovery timelines, in some instances halving them. That has a direct impact on retention, particularly when you consider that replacing an employee can cost anywhere from 100–200% of their salary, based on PwC workforce analyses.
On top of that, brokers bring leverage in a difficult insurance market. With premiums rising, their ability to use aggregated claims data to negotiate better terms becomes a material advantage, particularly around bundled mental health and neurological support. And importantly, this aligns with broader policy frameworks like the government’s Healthy Working Lifecycle.
What This Means for Leadership Teams
There’s a tendency to treat neurological conditions as isolated HR issues. That’s a mistake.
From an HR perspective, the risk is clear: failure to support employees properly increases exposure to disability discrimination claims under the Equality Act. With neurodivergent individuals making up as much as 20% of the workforce, this is not a marginal concern. Brokers help mitigate this by auditing schemes for inclusivity and ensuring access to VCSE-supported care in line with the 10-Year Health Plan.
For risk managers, the issue is escalation. Poorly managed conditions increase the likelihood of reportable occupational diseases and potential litigation. HSE data makes it clear that proactive intervention isn’t optional, rather it’s expected.
Finance teams are dealing with a different angle: cost leakage. With £3.3 billion spent annually on NHS neurological care, pressure inevitably spills into private claims. Brokers help contain this by focusing on early intervention — particularly through tailored employee assistance programmes designed for cognitive and neurological needs.
What I’d Be Asking My Broker Right Now
If you’re sitting at C-suite level, this isn’t something to delegate and forget. You need to actively engage your broker capability. At a minimum:
- Commission a full benefits audit specifically focused on neurological coverage gaps, benchmarked against Mercer standards, and grounded in the 16.5 million prevalence reality.
- Put quarterly claims reviews in place to surface chronic cases early and apply structured case management aligned with NICE guidance, targeting that 9.4-day absence average.
- Push for policy enhancements that include home-based neuro care and better digital integration, both are increasingly critical for retention.
- Bring broker insights into your risk register. Use HSE data to model exposure and justify investment decisions at board level.
- Make employee education part of the strategy. If people don’t understand the support available, utilisation and invariably impact stays low.[5]
The direction of travel is obvious. Neurological demand driven by an ageing workforce and post-pandemic system strain is rising. Trying to manage that complexity internally is inefficient at best and risky at worst.
The organisations getting ahead of this aren’t waiting for the system to improve. They’re bringing in specialist brokers and using them as an extension of their operating model.
If you haven’t pressure-tested your current setup against this reality, now is the time. Because the cost of getting this wrong doesn’t show up all at once. Instead, it accumulates quietly, until it’s impossible to ignore.